Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,580 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes (T1D) Clear all
Active, not recruiting No phase listed Observational

The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System

NCT05754281
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
2nd Gen LabPatch Glucose Sensing System
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 13, 2026, 5:12 PM EDT
Terminated Phase 2 Interventional

Study of Latiglutenase in T1D/CD Patients

NCT04839575
View directory record Official record
Conditions
Celiac Disease
Interventions
Latiglutenase, Placebo
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neulasta in Type 1 Diabetes

NCT00662519
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
Drug · Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

NCT03738865
View directory record Official record
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions
G-Pen, Novo Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Walnut Creek, California • Atlanta, Georgia • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 13, 2026, 5:12 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Testing an Integrated Care Model Trial

NCT06448429
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Usual care, Collaborative care model (CoCM)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 1 Interventional

Islet Transplantation for Patients With Type 1 Diabetes

NCT00073281
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet transplantation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Not applicable Interventional

Physical Activity and Glycemic Control in Adolescents

NCT02674828
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Reinforcement for meeting targeted physical activity goals, Standard of Care
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
13 Years to 24 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Not applicable Interventional Results available

Insul-In This Together Program for Adolescents With Type 1 Diabetes and Their Parents

NCT04589689
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insul-In This Together
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 13, 2026, 5:12 PM EDT
Not listed No phase listed Observational

Multivariable Artificial Pancreas: Detecting and Mitigating Unannounced Physical Activity and Acute Psychological Stress

NCT05145374
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
20 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 13, 2026, 5:12 PM EDT
Recruiting Not applicable Interventional

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

NCT07599982
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Interventions
MODI Algorithm
Device
Lead sponsor
DreaMed Diabetes
Industry
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Baltimore, Maryland • Detroit, Michigan • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

NCT00129259
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
Biological · Other · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 13, 2026, 5:12 PM EDT
Terminated Not applicable Interventional

Glucagon Counterregulation in Type 1 Diabetes

NCT03547427
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM, Acetaminophen test, Insulin-induced hypoglycemia, Exercise-induced hypoglycemia
Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Not applicable Interventional

Incorporating Mind-body Skills With Diabetes Education in Adolescents With Type 1 Diabetes

NCT05577169
View directory record Official record
Conditions
Type 1 Diabetes, Adolescent Behavior
Interventions
Mind-body skills, Diabetes education
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
15 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Not applicable Interventional Results available

CGM Use in Poorly Controlled Youth With Type 1 Diabetes

NCT04721145
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia, High Blood Sugar
Interventions
Dexcom G6 Continuous Glucose Monitor
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 13, 2026, 5:12 PM EDT
Recruiting Not applicable Interventional

Type 1 Diabetes and Obstructive Sleep Apnea

NCT06915831
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Type 1 Diabetes (T1D)
Interventions
Continuous positive airway pressure (CPAP)
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 2 Interventional

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

NCT06152042
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
North Miami Beach, Florida • Morehead City, North Carolina • Norman, Oklahoma + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 13, 2026, 5:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus

NCT02239354
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
VC-01™ Combination Product
Combination Product
Lead sponsor
ViaCyte
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes

NCT02372253
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Verapamil, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 13, 2026, 5:12 PM EDT
Completed No phase listed Observational Results available

Assessment of Mealtime Bolus Insulin Behavior

NCT03368807
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Escondido, California • Los Angeles, California • Ventura, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

NCT00046501
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
9 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

ATG-GCSF in New Onset Type 1 Diabetes

NCT02215200
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Reversing Type 1 Diabetes After it is Established

NCT01106157
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-Thymocyte Globin (ATG), Placebo, Pegylated GCSF
Drug
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

NCT02625636
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR438544, placebo, r-glucagon
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Oct 13, 2026, 5:12 PM EDT
Completed Not applicable Interventional

Shared Medical Appointments to Improve Outcomes in Adolescents With Type 1 Diabetes

NCT02547311
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Team Clinic
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
11 Years to 17 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 13, 2026, 5:12 PM EDT